Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GE HealthCare Technologies (GEHC) EBITDA (2022 - 2025)

GE HealthCare Technologies (GEHC) has disclosed EBITDA for 4 consecutive years, with $827.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 3.25% year-over-year to $827.0 million, compared with a TTM value of $2.8 billion through Dec 2025, up 5.26%, and an annual FY2025 reading of $2.8 billion, up 5.26% over the prior year.
  • EBITDA was $827.0 million for Q4 2025 at GE HealthCare Technologies, up from $653.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $827.0 million in Q4 2025 and bottomed at $509.0 million in Q1 2022.
  • Average EBITDA over 4 years is $646.6 million, with a median of $630.0 million recorded in 2022.
  • The sharpest move saw EBITDA dropped 11.33% in 2023, then rose 16.48% in 2025.
  • Year by year, EBITDA stood at $777.0 million in 2022, then fell by 11.33% to $689.0 million in 2023, then grew by 16.26% to $801.0 million in 2024, then grew by 3.25% to $827.0 million in 2025.
  • Business Quant data shows EBITDA for GEHC at $827.0 million in Q4 2025, $653.0 million in Q3 2025, and $654.0 million in Q2 2025.